Do GLP-1 Medications Help With Binge Eating? A Careful Look at the New Evidence
Semaglutide, tirzepatide, and their relatives have changed the conversation around weight, and many people taking them describe something unexpected: the constant mental noise about food quiets down. A new systematic review and meta-analysis asked whether that impression holds up under scientific scrutiny, specifically, whether GLP-1 receptor agonists reduce binge eating.
The researchers pooled 25 randomized controlled trials involving just over 8,000 participants, all of whom were living with overweight or obesity. Compared with placebo or other comparison treatments, people taking a GLP-1 medication reported modest reductions in binge eating severity, along with larger improvements in "disinhibited" eating (the sense that eating has gotten away from you) and in loss of control overeating. Emotional eating also improved. When the binge-eating measures were combined into a single outcome, the overall effect was moderate, the kind of change a person would likely notice, though not a transformation. Effects appeared strongest in the handful of trials that enrolled people diagnosed with binge eating disorder.
That last point deserves emphasis, because it is also the study's central weakness. Only three of the 25 trials recruited people with a formal binge eating disorder diagnosis, and those three trials contributed roughly 129 participants. Nearly everything else came from weight-loss or diabetes trials where eating behavior was measured as a side question, using brief self-report questionnaires rather than a clinical interview. Not one trial was rated as low risk of bias; twelve were rated high risk, and most were funded by the companies that make the drugs. Because these medications produce obvious effects, appetite suppression, nausea, weight change, participants can often guess which group they were assigned to, which tends to inflate self-reported improvement.
One finding cuts both ways. Participants on GLP-1 medications also reported more dietary restraint, more deliberate control over what and how much they ate. That can be healthy, flexible self-regulation. It can also be the rigid restriction that historically sets up the restrict-then-binge cycle in eating disorders. The trials were not designed to tell these apart, and the authors are appropriately candid that they cannot say which was happening.
There is also almost no long-term data. Most trials were short, and none followed people after stopping the medication, a meaningful gap given how commonly appetite and weight rebound after these drugs are discontinued. Participants were also predominantly white, middle-aged, and living with obesity, so nothing here speaks to binge eating in people at a normal weight.
What does this mean practically? These medications may be a reasonable adjunct for someone who has both obesity and binge eating symptoms, but adjunct is the operative word. The patient advisors who helped write the paper put it plainly: the medication is a tool, not a fix, and the psychological support still has to be there. If binge eating is part of your picture, it deserves direct treatment, whether or not a GLP-1 is in the plan.
Emptage I, Kozmér S, Cobham-Wilson A, et al. The effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on binge eating in patients with obesity: a systematic review and meta-analysis. eClinicalMedicine. Published online 2026. doi:10.1016/j.eclinm.2026.104007
